


## Curriculum Vitae

<b>Name</b>	<b>Chan Kim, MD, PhD</b>	
<b>Current Position &amp; Affiliation</b>	<b>Associate Professor, CHA Bundang Medical Center</b>	
<b>Country</b>	<b>Korea</b>	

### Educational Background

- 1999.3.-2005.2. MD, Yonsei University College of Medicine, Seoul, Korea.  
 2007.9.-2009.8. MS, Graduate School of Medicine, Yonsei University, Seoul, Korea.  
 2010.2.-2013.2. PhD, Korea Advanced Institute of Science and Technology, Daejeon, Korea.

### Professional Experience

- 2006.3.-2010.2. Residency in Internal Medicine, Yonsei University, Seoul, Korea  
 2013.3.-2014.2. Postdoctoral Fellow, Laboratory of Vascular Biology and Stem Cells, KAIST  
 2014.3.-2015.2. Clinical Fellow, Division of Medical Oncology, Yonsei University, Seoul, Korea  
 2015.3.-2015.8. Clinical Research Professor, Division of Medical Oncology, Yonsei University, Seoul, Korea  
 2015.9.-2020.2. Assistant Professor, Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea  
 2020.3.- Associate Professor, Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea

### Professional Organizations

Korean Cancer Association, Korean Society of Medical Oncology, American Association for Cancer Research, American Society of Clinical Oncology, The Society for Immunotherapy of Cancer

**Main Scientific Publications**

1. Lee SJ, Yang H, Kim WR, Lee YS, Lee WS, Kong SJ, Lee HJ, Kim JH, Cheon J, Kang B, Chon HJ, **Kim C.** **STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.**  
**J Immunother Cancer 2021 (IF 13.751) (Corresponding author)**
2. Lee YS, Lee WS, Kim CW, Lee SJ, Yang H, Kong SJ, Ning J, Yang KM, Kang B, Kim WR, Chon HJ, **Kim C.** **Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with PD-1 blockade to suppress peritoneal carcinomatosis in colon cancer.**  
**J Immunother Cancer 2020 (IF 13.751) (Corresponding author)**
3. Kim CG\*, **Kim C\***, Yoon SE\*, Kim KH, Kim HR, Park SH, Shin EC, Kim DJ, Chon HJ, Choi HJ, Lim HY. **Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. Journal of Hepatology 2020 (IF 25.083) (Co-first author)**
4. Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Kim S, Kim G, Chon HJ, **Kim C.** **STING Activation Reprograms Tumor Vasculatures and Synergizes with VEGFR2 Blockade. Journal of Clinical Investigation 2019 (IF 12.282) (Corresponding author)**
5. Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH, **Kim C.** **Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade. Clinical Cancer Research 2019 (IF 10.199) (Selected as Cover Image) (Corresponding author)**
6. **Kim C,** Yang H, Fukushima Y, Saw PE, Lee J, Park JS, Park I, Jung J, Kataoka H, Lee D, Heo WD, Kim I, Jon S, Adams RH, Nishikawa SI, Uemura A, Koh GY. **Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption. Cancer Cell 2014 (IF 24.755)**